(redirected from Acid Control)
Also found in: Dictionary, Thesaurus.


an antagonist of histamine H2receptors, inhibiting the action of histamine at cell surface receptors of the gastric parietal cells and reducing basal gastric acid secretion and secretion stimulated by food, histamine, gastrin, caffeine, and insulin. It is administered orally for the short-term (two months) treatment and, at reduced dosage, the long term prevention, of peptic ulcers, for the relief of symptoms associated with hyperacidity, such as heartburn and acid indigestion, and for the treatment of gastroesophageal reflux disease, upper gastrointestinal bleeding, and pathological hypersecretory conditions such as zollinger-ellison syndrome.


Apo-Famotidine (CA), Gen-Famotidine (CA), Maalox H2 Acid Controller, Mylanta AR, Novo-Famotidine (CA), Nu-Famotidine (CA), Pepcid, Pepcid AC, Ulcidine (CA), Ultra Heartburn Relief (UK)

Pharmacologic class: Histamine2-receptor antagonist

Therapeutic class: Antiulcer drug

Pregnancy risk category B


Blocks action of histamine at histamine2-receptor sites in gastric parietal cells, inhibiting gastric acid secretion and stabilizing pepsin


Gelcaps: 10 mg

Oral suspension: 40 mg/5 ml

Solution for injection: 10 mg/ml, 20 mg/50 ml of normal saline solution

Tablets: 10 mg, 20 mg, 40 mg

Tablets (chewable): 10 mg

Tablets (orally disintegrating): 20 mg, 40 mg

Indications and dosages

Active duodenal ulcers and benign gastric ulcers

Adults: 40 mg P.O. once daily at bedtime or 20 mg P.O. b.i.d. for up to 8 weeks

Prophylaxis of duodenal ulcers

Adults: 20 mg P.O. once daily at bedtime

Gastroesophageal reflux disease

Adults: 20 mg P.O. b.i.d. for up to 6 weeks. Maximum dosage is 40 mg b.i.d. for up to 12 weeks.

Children ages 1 to 16: 1 mg/kg P.O. daily in two divided doses, to a maximum of 40 mg b.i.d.

Infants ages 3 months to 1 year: 0.5 mg/kg P.O. b.i.d. for up to 8 weeks

Infants younger than age 3 months: 0.5 mg/kg P.O. once daily for up to 8 weeks

Gastric hypersecretory conditions (such as Zollinger-Ellison syndrome)

Adults: Initially, 20 mg P.O. q 6 hours, increased as needed to 160 mg q 6 hours

Hospitalized patients with pathologic hypersecretory conditions or ulcers; patients who can't take oral drugs

Adults: 20 mg I.V. q 12 hours

Prevention or treatment of heartburn, acid indigestion, and sour stomach (Pepcid AC only)

Adults: For prevention, 10 mg P.O. 1 hour before eating, or 10-mg chewable tablet 15 minutes before eating, to a maximum of 20 mg/24 hours for up to 2 weeks. For symptomatic treatment, 10 mg P.O. once or twice daily.

Dosage adjustment

• Renal impairment


• Hypersensitivity to drug or other histamine2-receptor antagonists


Use cautiously in:
• renal impairment with prolonged QT interval and seizures (very rare)
• elderly patients
• pregnant or breastfeeding patients.


• Be aware that drug usually is given in one daily dose to patients with renal insufficiency.
• Give P.O. form with foods or liquids.
• Dilute I.V. form with 10 ml dextrose 5% in water or normal saline solution (100 ml) for I.V. piggyback administration.
• Deliver by I.V. push over 2 minutes or intermittent infusion over 30 minutes.
• Know that drug may cause transient irritation at I.V. site.

Adverse reactions

CNS: dizziness, headache, paresthesia, asthenia, fatigue, insomnia, somnolence, psychic disturbances

CV: palpitations, arrhythmias, AV block

GI: nausea, vomiting, diarrhea, constipation, dry mouth, anorexia, cholestatic jaundice, abdominal pain

GU: decreased libido

Hematologic: agranulocytosis, pancytopenia, leukopenia, thrombocytopenia (rare)

Hepatic: liver enzyme abnormalities, hepatitis

EENT: orbital edema, conjunctival redness, tinnitus

Musculoskeletal: musculoskeletal pain, muscle cramps, arthralgia

Respiratory: bronchospasm, interstitial pneumonia

Skin: flushing, acne, dry skin, rash, urticaria, alopecia, pruritus; epidermal necrolysis and Stevens-Johnson syndrome (very rare)

Other: altered taste, fever, pain at injection site, hypersensitivity reactions including anaphylaxis and angioedema


Drug-diagnostic tests.Liver enzymes: altered levels

Patient monitoring

• Assess patient for GI signs and symptoms.
• Monitor blood urea nitrogen and creatinine levels in patients with renal impairment.

Monitor patient for prolonged QT interval and seizures, which have been reported very rarely in patients with impaired renal function whose famotidine dosage or dosing interval may not have been adjusted appropriately. Also monitor patient for arrhythmia and AV block.

Monitor patient for signs and symptoms of epidermal necrolysis, Stevens-Johnson syndrome, and hematologic or respiratory changes.

Patient teaching

• Tell patient that drug is most effective when taken at bedtime.
• Inform patient that pain relief may not begin until several days after therapy starts.

Instruct patient to take drug exactly as prescribed and to immediately report cardiovascular signs and symptoms, seizures, and hematologic or respiratory changes.
• Tell female patient to inform prescriber if she is pregnant or breastfeeding.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


/fam·o·ti·dine/ (fam-o´tĭ-dēn) a histamine H2 receptor antagonist, which inhibits gastric acid secretion; used in the treatment and prophylaxis of gastric or duodenal ulcers, gastroesophageal reflux disease, upper gastrointestinal bleeding, and conditions associated with gastric hypersecretion.


A histamine antagonist, C8H15N7O2S3, that inhibits the secretion of gastric acid and is used to treat duodenal and gastric ulcers and gastroesophageal reflux disease.


an oral and parenteral antiulcer drug; an H2-receptor antagonist.
indications It is prescribed in treatment of duodenal ulcer and pathological hypersecretory conditions, and for stress-ulcer prophylaxis.
contraindications Famotidine should be used with caution in patients with impaired kidney function.
adverse effects Among adverse effects reported are headache, dizziness, constipation, diarrhea, and temporary irritation of the injection site.


Pepcid Therapeutics An agent used to treat peptic ulcer disease by blocking binding of histamine to H2 receptors, resulting in ↓ intracellular concentration of cAMP and acid secretion by gastric parietal cells Adverse reactions Diarrhea, headache, drowsiness, fatigue, muscle pain, constipation, rarely, also mental confusion, agranulocytosis, gynecomastia, impotence, allergic reactions, myalgias, tachycardia, arrhythmias, interstitial nephritis, etc. See Histamine receptor antagonist.


An H2 RECEPTOR ANTAGONIST drug used to treat peptic ulcers and reflux oesophagitis (heartburn). A brand name is Pepsid.


n brand names: Pepcid, Pepcid IV;
drug class: H2-histamine receptor antagonist;
action: inhibits histamine at H2 receptor site in parietal cells, which inhibits gastric acid secretion;
uses: short-term treatment of active duodenal ulcer, gastric ulcer, and heartburn.


a histamine H2-receptor antagonist, similar to cimetidine.
References in periodicals archive ?
The bill on Acid Control and Acid Crime Prevention a jail term of 14 years life imprisonment and fines up to one million rupees for the perpetrators of the crime.
Secondary objectives of the study were to evaluate among the three treatment arms the AUC (area under the curve) of plasma uric acid from baseline through 48 hours after the last planned anti-hyperuricemic treatment, the time to plasma uric acid control, safety (including immunogenicity) and pharmacokinetics.
Control systems - The El Dorado Facility main nitric acid control room structure was destroyed by the explosion; however, most of the controls remained intact.
Coming on the heels of "Prevention of Anti-Women Practices Bill, 2008" and " Acid Control and Acid Crime Prevention Act, 2011", this bill, once enacted into law, will herald a significant change in the condition of women across the country.
Efficacy endpoints will include the level of uric acid control, an assessment of the reduction in burden of gout tophi using digital photography, reduction in the frequency of gout flares, improvement in the count of swollen and tender joints, and improvements in patient reported outcomes using the Short Form 36 (SF-36) and the Health Assessment Questionnaire-Disability Index (HAQ-DI).
He stated that to ensure and empower women in the country, protection of women comprehensive legislation has also been done including the Prevention of Anti-Women Practices Act, Acid Control and Acid Crime Prevention Act and Laws on Sexual Harassment.
The landmark legislations passed by the present Government on The Prevention of Anti-Women Practices (Criminal Law Amendment) Act2011 and The Acid Control and The Acid Crimes Prevention (Criminal Law Amendment) Act 2011 and The Protection against Harassment of Women at the Workplace Act, 2010 should be extended to FATA region, the letter said.
ZEGERID products offer a distinct pharmacological profile - rapidly reaching maximal plasma levels (in approximately 30 minutes) and providing strong acid control.
ISLAMABAD, April 27, 2011 (Frontier Star): The National Assembly Tuesday unanimously approved the Acid Control and Acid Crime Prevention Bill, 2010.
Gastric acid control was defined as intragastric pH > 4.
CHICAGO, May 16 /PRNewswire-FirstCall/ -- Data from a clinical trial comparing stomach acid control of three proton pump inhibitors (PPIs), esomeprazole magnesium (NEXIUM(R)), lansoprazole (Prevacid), and pantoprazole (Protonix), in chronic users of non-steroidal anti-inflammatory drugs (NSAIDs) were presented today at the annual Digestive Disease Week(R) (DDW(R)).